Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Mesoblast Limited (NASDAQ:MESO) is an Australian biopharmaceutical company founded in 2004 and headquartered in Melbourne. The company specializes in developing and commercializing allogeneic cellular medicines based on mesenchymal stromal cells (MSCs), a type of adult stem cell. Mesoblast went public in 2010 and has since established itself as a pioneer in the regenerative medicine field. The company achieved a significant milestone in 2024 with the FDA approval of <b>RYONCIL</b>, the first mesenchymal stromal cell therapy approved in the United States, marking its transition from a pure development-stage company to one with commercial operations.
Latest newsMore news →
Mesoblast Limited reported financial results for the fiscal year ended June 30, 2026, with substantial revenue growth to US$120 million and gross profit of US$104 million.25d agoMesoblast Limited completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain, with 350 patients randomized and treated.35d ago